ORIC Pharmaceuticals Inc
ORICHealthcare|Biotechnology|USA
$10.85
-0.09 (-0.82%)
Tangible Book
$4.02
Earnings Power
$2.52
Upcoming Data Readouts (3)
Sep 2026
Est. completion
P1P2Solid Tumors
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT05315700n=350
Dec 2026
Est. completion
P1Solid Tumors
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
NCT06816992n=76
Jun 2027
Est. completion
P1Metastatic Prostate Cancer
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT05413421n=275